Lucentis

Roche maintains top place in biologic sales

It also has a strong showing from across its drug portfolio, with its breast cancer drug Herceptin (trastuzumab) bringing in more than CHF6bn last year, with eye drug Lucentis (ranibizumab) and

Trials of Roche's new blindness candidate now underway

Roche and partner Novartis already market their vascular endothelial growth factor (VEGF) inhibitor Lucentis (ranibizumab) for the wet or neovascular form of AMD, as well as macular oedema caused by diabetes ... While multiple therapies exist for wet

The BMJ weighs in on Avastin/Lucentis debate

ahead of Lucentis and Eylea for years, predominately because it is around a tenth of the price of the licensed medicines. ... In fact, Roche co-markets Lucentis with Novartis in certain markets as Lucentis is the 'chemical cousin' of Avastin.

Bayer's Eylea cleared for wider use in Europe

population. Eylea was approved to treat DME in the US last July and in Europe the following month, while Lucentis has had that indication on its label since 2012. ... Lucentis' growth this year - with the potential for flat or even a modest decline in

UK doctors call on NHS to use Avastin for wet AMD

Avastin only has cancer licences, but it is chemically similar to Lucentis, meaning it can be successfully used for wet AMD. ... In fact, Roche co-markets Lucentis with Novartis in certain markets as Lucentis is the 'chemical cousin' of Avastin.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]